Interferometric Observations of Explosive Variables: V838 Mon, Nova Aql 2005, and RS Oph

During the last two years we have used the Palomar Testbed Interferometer to observe several explosive variable stars, including V838 Monocerotis, V1663 Aquilae and recently RS Ophiuchi. We observed V838 Monocerotis approximately 34 months after its eruption, and were able to resolve the ejecta. Observations of V1663 Aql were obtained starting 9 days after peak brightness and continued for 10 days. We were able to resolve the milliarcsecond-scale emission and follow the expansion of the nova photosphere. When combined with radial-velocity information, these observations can be used to infer the distance to the nova. Finally we have resolved the recurrent nova RS Oph and can draw some preliminary conclusions regarding the emission morphology.Comment: 8 Pages, SPIE Astronomical Telescopes and Instrumentation 2006, Advances in Stellar Interferometery, 6268-16

Splenectomy during secondary cytoreduction for ovarian cancer disease recurrence: Surgical and survival data

Ovarian cancer disease recurs predominantly in the abdomen, with the spleen usually involved as part of a vast spread of upper-abdominal disease or, less frequently, as an isolated site of disease recurrence. Very few reports are available in the literature on the outcome of patients subjected to splenectomy during secondary cytoreduction. The aim of this study was to identify prognostic factors and to review surgical and clinical data in order to identify those patients who would benefit the most from splenectomy during secondary cytoreduction. This was a retrospective review of platinum-sensitive recurrent epithelial ovarian cancer patients who underwent splenectomy as part of secondary cytoreduction. Surgical and survival data were recorded. Twenty-four patients were identified. Multiple site disease recurrence was observed in 15 patients. The spleen was involved at the hilus in 12 patients; surface and intraparenchymal metastases were equally present. Optimal cytoreduction was achieved in all patients. At a median follow-up of 30 months, median progression-free and overall survival from the time of secondary surgery were 34 and 56 months, respectively. Overall survival was significantly correlated to residual disease at secondary surgery, disease-free survival, consolidation chemotherapy, and type of adjuvant therapy. Splenectomy as part of secondary cytoreduction is a feasible and safe procedure. Secondary cytoreduction in selected groups of patients is confirmed to be associated with high long-term survival rates even when aggressive surgery of the upper abdomen is required